Sentinel Node Biopsy for Thin Melanomas: Which Patient Should Be Considered?
Christopher A. Puleo, PA-C; Jane L. Messina, MD; Adam I. Riker, MD; L. Frank Glass, MD; Christopher Nelson, MD; C. Wayne Cruse, MD; Timothy M. Johnson, MD; Vernon K. Sondak, MD

Head and Neck Melanoma
Matthew A. Kienstra, MD; Tapan A. Padhya, MD

Choices in Adjuvant Therapy for Melanoma
David H. Lawson, MD

Cutaneous Melanoma: Prognostic Factors
Jade Homsi, MD, Mohammed Kashani-Sabet, MD, Jane L. Messina, MD, Adil Daud, MD

Chemoprevention of Melanoma: Theoretical and Practical Considerations
Marie-France Demierre, MD, FRCPC, Vernon K. Sondak, MD

Vaccines for Melanoma
C. Dean Buckner, MD

Adjuvant Alfa Interferon Modestly Effective in High-risk Melanoma (3/5/2010)
Researchers from Italy have concluded, on the basis of a systematic review and meta-analysis, that adjuvant alpha interferon significantly improves disease-free survival (DFS) and overall survival (OS) in patients with high-risk melanoma. The details of this study appeared in an early online publication on February 23, 2010 in the Journal of the National Cancer Institute.

Hispanics and African Americans Present with More Advanced Cutaneous Melanoma than Whites (1/4/2010)
Researchers from Florida have reported that Hispanics and African Americans present with more advanced melanomas than their White counterparts. The details of this study appeared in the December, 2009 issue of the Archives of Dermatology.

Ipilimumab Produces Responses in Patients with Metastatic Melanoma (12/22/2009)
Researchers affiliated with an international randomized Phase II clinical trial have reported dose-dependent responses in patients with advanced melanoma receiving ipilimumab. The details of this study appeared in an early online publication in Lancet Oncology on December 9, 2009.

GM-CSF-based Second-generation Oncolytic Herpesvirus Vaccine Promising for Melanoma (12/2/2009)
Researchers involved in an international multicenter clinical Phase II trial have reported a 26% response rate for patients with metastatic melanoma treated with a second-generation granulocyte-macrophage colony-stimulating factor (GM-CSF) oncolytic herpes simplex virus (HSV) vaccine. The details of this study were published in the December 1, 2009 issue of the Journal of Clinical Oncology.

Adjuvant Radiotherapy Improves Local Control in High-risk Melanoma Patients (11/12/2009)
Researchers affiliated with the Intergroup Randomized Trial (TROG 01.01/ANZMTG 01.02) have reported that adjuvant radiotherapy (RT) improves regional control for patients with high-risk melanoma without a statistically significant effect on survival. The details of this study were presented at the 2009 meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).